comparemela.com
Home
Live Updates
UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments : comparemela.com
UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments
Both ENVISION and ATLAS Phase 3 trials of UGN-102 met primary endpoints in treating low-grade intermediate-risk non‐muscle‐invasive bladder cancer .
Reported record JELMYTO® net product...
-Today at 08:05 am- MarketScreener
Related Keywords
Israel
,
Urogen Pharma
,
Urogen Rtgel
,
Liz Barrett
,
Twitter
,
Urogen Pharma Ltd
,
Nasdaq
,
Drug Administration
,
Chief Executive Officer
,
New Drug Application
,
Prepaid Forward Obligation
,
Long Term Debt
,
Pharmakon Advisors
,
Cash Equivalents
,
Operating Expense
,
Webcast Information
,
Upper Tract Urothelial Cancer
,
Prescribing Information
,
Patient Information
,
United Statesbetween
,
Private Securities Litigation Reform Act
,
Risk Factors
,
Quarterly Report
,
Markets
,
comparemela.com © 2020. All Rights Reserved.